Sponsors (2)
The bill increases PBM accountability and transparency for plan beneficiaries but raises the risk of higher costs, administrative burdens, and potential short-term disruptions to coverage as stakeholders adjust to fiduciary duties.
Millions of group health plan participants (including patients with chronic conditions) would see PBMs legally required to act in plans' best interests, reducing conflicts of interest in drug management and potentially improving plan decision-making.
Plan sponsors, beneficiaries, and state governments would gain clearer disclosure and fiduciary-responsibility rules that increase transparency about PBM arrangements, price concessions, and revenue flows.
Hospitals, health systems, and plan beneficiaries would have improved ability to hold PBMs and related entities financially accountable because indemnification protections would be removed, facilitating recovery for breaches of duty.
Small businesses and middle-class families could face higher premiums or reduced benefits if PBMs and TPAs pass on increased litigation and liability costs from fiduciary exposure.
Patients (including those with chronic conditions) and Medicaid beneficiaries may experience short-term disruptions in drug access or formulary coverage if insurers or plan sponsors shift services, raise administrative fees, or terminate PBM contracts in response to the changes.
Employers, state governments, and plan administrators could face higher compliance burdens and operational complexity to enforce fiduciary duties, increasing paperwork and administrative costs.
Based on analysis of 2 sections of legislative text.
Designates PBMs and certain pharmacy administrators as ERISA fiduciaries for formulary/network management, rebate negotiation, claims processing, and utilization management, and bars indemnification for those fiduciary duties.
Treats pharmacy benefit managers (PBMs) and certain pharmacy third‑party administrators as ERISA fiduciaries when they run drug networks or formularies, negotiate or aggregate rebates/discounts, process and pay prescription drug claims, or conduct utilization review/management. It also amends ERISA rules to require greater disclosure and clarifies which parties are responsible, removes indemnification protections for those newly deemed fiduciaries, and phases the change in for plan years beginning at least 12 months after enactment. The change shifts legal duties onto PBMs/TPAs and affects group health plan sponsors, insurers, plan administrators, pharmacies, and plan participants — increasing compliance and disclosure obligations and likely changing contract, claims-payment, and pricing arrangements for employer-sponsored prescription drug benefits.
Introduced December 18, 2025 by Jake Auchincloss · Last progress December 18, 2025